Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CorMedix Inc.CRMD · Entity 5280 | Chief Scientific Officer | February 07, 2017 | February 08, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CorMedix Inc.
Report date February 07, 2017 · Filed February 08, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2017-02-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-02-07 · Exercise / conversion · Acquired 10,000 · Balance 10,000 Row 2 · 2017-02-07 · Sale · Disposed 10,000 · Balance 0 F1: This exercise and sale was effected pursuant to a Rule 10b5-1 trading plan executed by the reporting person on September 19, 2016. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.68 · Expires 2022-12-05 | Direct | 70,000 |
Reported balance
After 2017-02-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-02-07 · Exercise / conversion · Acquired 10,000 · Balance 70,000 F1: This exercise and sale was effected pursuant to a Rule 10b5-1 trading plan executed by the reporting person on September 19, 2016. F2: These options vested as follows: fifty percent (50%) on the date of issuance of the CE mark certification, which occurred on July 5, 2013, and (b) fifty percent (50%) on December 31, 2013. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.10 · Expires 2021-01-14 | Direct | 30,000 |
Reported balance
Holding disclosure · report date 2017-02-07 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 30,000 F4: These options vested on January 14, 2012. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.90 · Expires 2023-03-22 | Direct | 210,000 |
Reported balance
Holding disclosure · report date 2017-02-07 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 210,000 F5: These options vest based on performance milestones running through December 31, 2014. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.02 · Expires 2024-01-09 | Direct | 30,000 |
Reported balance
Holding disclosure · report date 2017-02-07 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 30,000 F6: The options vest in full on the first anniversary of the date of grant. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.02 · Expires 2024-01-09 | Direct | 100,000 |
Reported balance
Holding disclosure · report date 2017-02-07 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 100,000 F7: The options vested 100% on January 10, 2014. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.27 · Expires 2024-04-01 | Direct | 100,000 |
Reported balance
Holding disclosure · report date 2017-02-07 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 100,000 F8: The options vested 100% on April 2, 2014. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.00 · Expires 2025-02-24 | Direct | 75,000 |
Reported balance
Holding disclosure · report date 2017-02-07 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 75,000 F9: These options were granted on February 24, 2015, and vested immediately. |
| stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.13 · Expires 2020-03-30 | Direct | 20,000 |
Reported balance
Holding disclosure · report date 2017-02-07 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 20,000 F3: These options vested as follows: 1/3 on March 30, 2010; an additional 1/3 on March 30, 2011; and the remaining 1/3 on March 30, 2012. |
Filing footnotes · ownership attribution and instrument terms
F1: This exercise and sale was effected pursuant to a Rule 10b5-1 trading plan executed by the reporting person on September 19, 2016.
F2: These options vested as follows: fifty percent (50%) on the date of issuance of the CE mark certification, which occurred on July 5, 2013, and (b) fifty percent (50%) on December 31, 2013.
F3: These options vested as follows: 1/3 on March 30, 2010; an additional 1/3 on March 30, 2011; and the remaining 1/3 on March 30, 2012.
F4: These options vested on January 14, 2012.
F5: These options vest based on performance milestones running through December 31, 2014.
F6: The options vest in full on the first anniversary of the date of grant.
F7: The options vested 100% on January 10, 2014.
F8: The options vested 100% on April 2, 2014.
F9: These options were granted on February 24, 2015, and vested immediately.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 07, 2017 Filed Feb 8, 2017 21:01 UTC | CorMedix Inc. CRMD · Entity 5280 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001354488-17-000231 · issuerdirect_section16.xml · derivative · entry 3 Pfaffle Antony · CIK 0001368953 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock, $0.001 par value per share · 10,000 shares Expires 2022-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale was effected pursuant to a Rule 10b5-1 trading plan executed by the reporting person on September 19, 2016. F2 · derivative.exercise_date: These options vested as follows: fifty percent (50%) on the date of issuance of the CE mark certification, which occurred on July 5, 2013, and (b) fifty percent (50%) on December 31, 2013. Read SEC document |
| February 07, 2017 Filed Feb 8, 2017 21:01 UTC | CorMedix Inc. CRMD · Entity 5280 | SaleCommon Stock | 10,000 | $2.00 | $20,000.00 |
DisclosureSEC source: 0001354488-17-000231 · issuerdirect_section16.xml · nonDerivative · entry 2 Pfaffle Antony · CIK 0001368953 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This exercise and sale was effected pursuant to a Rule 10b5-1 trading plan executed by the reporting person on September 19, 2016. Read SEC document |
| February 07, 2017 Filed Feb 8, 2017 21:01 UTC | CorMedix Inc. CRMD · Entity 5280 | Exercise / conversionCommon Stock | 10,000 | $0.68 | $6,800.00 |
DisclosureSEC source: 0001354488-17-000231 · issuerdirect_section16.xml · nonDerivative · entry 1 Pfaffle Antony · CIK 0001368953 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 21, 2016 Filed Oct 25, 2016 20:32 UTC | CorMedix Inc. CRMD · Entity 5280 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001354488-16-008420 · issuerdirect_section16.xml · derivative · entry 3 Pfaffle Antony · CIK 0001368953 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock, $0.001 par value per share · 20,000 shares Expires 2022-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale was effected pursuant to a Rule 10b5-1 trading plan executed by the reporting person on September 19, 2016. F3 · derivative.exercise_date: These options vested as follows: (a) fifty percent (50%) on the date of the issuance of the CE mark certification, which occurred on July 5th, 2013, and (b) fifty percent (50%) on December 31, 2013. Read SEC document |
| October 21, 2016 Filed Oct 25, 2016 20:32 UTC | CorMedix Inc. CRMD · Entity 5280 | SaleCommon Stock, $0.001 par value per share | 20,000 | $2.23 | $44,600.00 |
DisclosureSEC source: 0001354488-16-008420 · issuerdirect_section16.xml · nonDerivative · entry 2 Pfaffle Antony · CIK 0001368953 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This exercise and sale was effected pursuant to a Rule 10b5-1 trading plan executed by the reporting person on September 19, 2016. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.226 to $2.228, inclusive. Read SEC document |
| October 21, 2016 Filed Oct 25, 2016 20:32 UTC | CorMedix Inc. CRMD · Entity 5280 | Exercise / conversionCommon Stock, $0.001 par value per share | 20,000 | $0.68 | $13,600.00 |
DisclosureSEC source: 0001354488-16-008420 · issuerdirect_section16.xml · nonDerivative · entry 1 Pfaffle Antony · CIK 0001368953 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.